Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1186 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rheumatoid Arthritis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape. Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively. Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology). - The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 12 Rheumatoid Arthritis Overview 13 Therapeutics Development 14 Rheumatoid Arthritis - Therapeutics under Development by Companies 16 Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36 Rheumatoid Arthritis - Pipeline Products Glance 39 Rheumatoid Arthritis - Products under Development by Companies 43 Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 72 Rheumatoid Arthritis - Companies Involved in Therapeutics Development 75 Rheumatoid Arthritis - Therapeutics Assessment 308 Drug Profiles 355 Rheumatoid Arthritis - Dormant Projects 1046 Rheumatoid Arthritis - Discontinued Products 1098 Rheumatoid Arthritis - Product Development Milestones 1110 Appendix 1134
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H2 2016 65 Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016 66 Number of Products under Development by Companies, H2 2016 68 Number of Products under Development by Companies, H2 2016 (Contd..1) 69 Number of Products under Development by Companies, H2 2016 (Contd..2) 70 Number of Products under Development by Companies, H2 2016 (Contd..3) 71 Number of Products under Development by Companies, H2 2016 (Contd..4) 72 Number of Products under Development by Companies, H2 2016 (Contd..5) 73 Number of Products under Development by Companies, H2 2016 (Contd..6) 74 Number of Products under Development by Companies, H2 2016 (Contd..7) 75 Number of Products under Development by Companies, H2 2016 (Contd..8) 76 Number of Products under Development by Companies, H2 2016 (Contd..9) 77 Number of Products under Development by Companies, H2 2016 (Contd..10) 78 Number of Products under Development by Companies, H2 2016 (Contd..11) 79 Number of Products under Development by Companies, H2 2016 (Contd..12) 80 Number of Products under Development by Companies, H2 2016 (Contd..13) 81 Number of Products under Development by Companies, H2 2016 (Contd..14) 82 Number of Products under Development by Companies, H2 2016 (Contd..15) 83 Number of Products under Development by Companies, H2 2016 (Contd..16) 84 Number of Products under Development by Companies, H2 2016 (Contd..17) 85 Number of Products under Development by Companies, H2 2016 (Contd..18) 86 Number of Products under Investigation by Universities/Institutes, H2 2016 87 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 88 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 89 Comparative Analysis by Late Stage Development, H2 2016 90 Comparative Analysis by Clinical Stage Development, H2 2016 91 Comparative Analysis by Early Stage Development, H2 2016 92 Comparative Analysis by Unknown Stage Development, H2 2016 93 Products under Development by Companies, H2 2016 94 Products under Development by Companies, H2 2016 (Contd..1) 95 Products under Development by Companies, H2 2016 (Contd..2) 96 Products under Development by Companies, H2 2016 (Contd..3) 97 Products under Development by Companies, H2 2016 (Contd..4) 98 Products under Development by Companies, H2 2016 (Contd..5) 99 Products under Development by Companies, H2 2016 (Contd..6) 100 Products under Development by Companies, H2 2016 (Contd..7) 101 Products under Development by Companies, H2 2016 (Contd..8) 102 Products under Development by Companies, H2 2016 (Contd..9) 103 Products under Development by Companies, H2 2016 (Contd..10) 104 Products under Development by Companies, H2 2016 (Contd..11) 105 Products under Development by Companies, H2 2016 (Contd..12) 106 Products under Development by Companies, H2 2016 (Contd..13) 107 Products under Development by Companies, H2 2016 (Contd..14) 108 Products under Development by Companies, H2 2016 (Contd..15) 109 Products under Development by Companies, H2 2016 (Contd..16) 110 Products under Development by Companies, H2 2016 (Contd..17) 111 Products under Development by Companies, H2 2016 (Contd..18) 112 Products under Development by Companies, H2 2016 (Contd..19) 113 Products under Development by Companies, H2 2016 (Contd..20) 114 Products under Development by Companies, H2 2016 (Contd..21) 115 Products under Development by Companies, H2 2016 (Contd..22) 116 Products under Development by Companies, H2 2016 (Contd..23) 117 Products under Development by Companies, H2 2016 (Contd..24) 118 Products under Development by Companies, H2 2016 (Contd..25) 119 Products under Development by Companies, H2 2016 (Contd..26) 120 Products under Development by Companies, H2 2016 (Contd..27) 121 Products under Development by Companies, H2 2016 (Contd..28) 122 Products under Investigation by Universities/Institutes, H2 2016 123 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 124 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 125 Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2016 126 Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2016 127 Rheumatoid Arthritis - Pipeline by A&G Pharmaceutical Inc, H2 2016 128 Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2016 129 Rheumatoid Arthritis - Pipeline by AB2 Bio Ltd, H2 2016 130 Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2016 131 Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2016 132 Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H2 2016 133 Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2016 134 Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H2 2016 135 Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H2 2016 136 Rheumatoid Arthritis - Pipeline by AlphaMab Co Ltd, H2 2016 137 Rheumatoid Arthritis - Pipeline by Alteogen Inc, H2 2016 138 Rheumatoid Arthritis - Pipeline by Amgen Inc, H2 2016 139 Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd, H2 2016 140 Rheumatoid Arthritis - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 141 Rheumatoid Arthritis - Pipeline by AnGes MG Inc, H2 2016 142 Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H2 2016 143 Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H2 2016 144 Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 145 Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 146 Rheumatoid Arthritis - Pipeline by arGEN-X BV, H2 2016 147 Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 148 Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2016 149 Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H2 2016 150 Rheumatoid Arthritis - Pipeline by Asana BioSciences LLC, H2 2016 151 Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H2 2016 152 Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H2 2016 153 Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H2 2016 154 Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 155 Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2016 156 Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2016 157 Rheumatoid Arthritis - Pipeline by BCN Peptides SA, H2 2016 158 Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 159 Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 160 Rheumatoid Arthritis - Pipeline by Biocad, H2 2016 161 Rheumatoid Arthritis - Pipeline by Biocon Ltd, H2 2016 162 Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd, H2 2016 163 Rheumatoid Arthritis - Pipeline by BioLingus AG, H2 2016 164 Rheumatoid Arthritis - Pipeline by BioLite Inc, H2 2016 165 Rheumatoid Arthritis - Pipeline by Bionovis SA, H2 2016 166 Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc, H2 2016 167 Rheumatoid Arthritis - Pipeline by Biozeus, H2 2016 168 Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H2 2016 169 Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 170 Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 171 Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H2 2016 172 Rheumatoid Arthritis - Pipeline by Cardax Inc, H2 2016 173 Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 174 Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H2 2016 175 Rheumatoid Arthritis - Pipeline by Celgene Corp, H2 2016 176 Rheumatoid Arthritis - Pipeline by Cellceutix Corp, H2 2016 177 Rheumatoid Arthritis - Pipeline by Celldex Therapeutics Inc, H2 2016 178 Rheumatoid Arthritis - Pipeline by Celltrion Inc, H2 2016 179 Rheumatoid Arthritis - Pipeline by ChemoCentryx Inc, H2 2016 180 Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2016 181 Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2016 182 Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 183 Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H2 2016 184 Rheumatoid Arthritis - Pipeline by Clevexel Pharma SA, H2 2016 185 Rheumatoid Arthritis - Pipeline by CLL Pharma SA, H2 2016 186 Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H2 2016 187 Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H2 2016 188 Rheumatoid Arthritis - Pipeline by Compugen Ltd, H2 2016 189 Rheumatoid Arthritis - Pipeline by Confluence Life Sciences Inc, H2 2016 190 Rheumatoid Arthritis - Pipeline by CSL Ltd, H2 2016 191 Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 192 Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 193 Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 194 Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H2 2016 195 Rheumatoid Arthritis - Pipeline by Domainex Ltd, H2 2016 196 Rheumatoid Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 197 Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 198 Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H2 2016 199 Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2016 200 Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 201 Rheumatoid Arthritis - Pipeline by Endocyte Inc, H2 2016 202 Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H2 2016 203 Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 204 Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H2 2016 205 Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2016 206 Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H2 2016 207 Rheumatoid Arthritis - Pipeline by Genentech Inc, H2 2016 208 Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016 209 Rheumatoid Arthritis - Pipeline by Genosco Inc, H2 2016 210 Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H2 2016 211 Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H2 2016 212 Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2016 213 Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H2 2016 214 Rheumatoid Arthritis - Pipeline by Handok Inc, H2 2016 215 Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 216 Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H2 2016 217 Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H2 2016 218 Rheumatoid Arthritis - Pipeline by HEC Pharm Co Ltd, H2 2016 219 Rheumatoid Arthritis - Pipeline by Hetero Drugs Ltd, H2 2016 220
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
